Multiple myeloma, Stem cell transplantation, Regimen-related toxicity, Experimental therapeutics and cancer pharmacology, Non-myeloid injury including VOD and mucocytis in bone marrow transplantation. Currently, I am leading multiple efforts studying the use of combination therapies predominantly in relapsed and refractory myeloma, an area of primary interest to me. I also serve as a principal investigator and study chairman for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity. My major leadership efforts are focused on the IFM/DFCI upfront study in patients eligible for stem cell transplant in combination with RVD. Finally, an important new area of interest for me is treatment-emergent neuropathy in myeloma, its characterization and strategies to minimize it.